What Is Spinal Muscular Atrophy?
Spinal Muscular Atrophy (SMA) is an inherited neuromuscular disorder that causes progressive muscle weakness. It occurs when motor neurons, which control voluntary muscle movement, are damaged or lost.
SMA can affect babies, children, teenagers, and adults. The age at which symptoms begin and the severity of weakness can vary considerably between individuals.
What Causes Spinal Muscular Atrophy?
The most common form of SMA is associated with changes in the SMN1 gene. This gene provides instructions for producing survival motor neuron (SMN) protein, which is important for normal motor neuron function.
When both copies of the SMN1 gene are affected by disease-causing variants, insufficient functional SMN protein can lead to motor neuron degeneration and muscle weakness.
Another gene called SMN2 can influence the severity of SMA. The number of SMN2 copies varies between individuals and may be associated with differences in disease severity, although it cannot perfectly predict how the condition will progress.
What Are the Types of SMA?
SMA is traditionally classified into Types 1, 2, 3, and 4 based mainly on the age when symptoms begin and the motor abilities achieved.
SMA Type 1 usually begins during infancy and is one of the most severe forms of SMA.
Babies may develop severe muscle weakness, low muscle tone, difficulty holding their head up, feeding problems, and breathing difficulties.
SMA Type 2 usually develops during infancy or early childhood. Children may be able to sit independently but often have difficulty standing or walking without assistance.
Muscle weakness can progressively affect mobility and other physical activities.
SMA Type 3 generally develops later in childhood or adolescence, although the age of onset can vary.
Children with SMA Type 3 may initially walk independently but can develop difficulty running, climbing stairs, getting up from the floor, or keeping up with other children physically.
SMA Type 4 generally has an adult onset and tends to have a milder presentation than earlier-onset forms.
Adults may gradually develop weakness around the hips, thighs, shoulders, or other proximal muscles. Difficulty walking, climbing stairs, or lifting objects may become noticeable over time.
How Is Spinal Muscular Atrophy Diagnosed?
Diagnosis usually begins with a medical history and neurological examination. Doctors may assess muscle strength, reflexes, motor development, and the pattern of weakness.
Additional investigations may be recommended depending on the individual’s symptoms.
Genetic testing is an important part of diagnosing SMN1-related SMA. Molecular testing can help identify disease-causing changes in the SMN1 gene and distinguish SMA from other neuromuscular conditions.
What Is SMN1 Genetic Testing?
An SMN1 genetic test examines the SMN1 gene for genetic changes associated with spinal muscular atrophy.
Testing may involve different molecular techniques depending on the suspected genetic change. Copy-number analysis can identify common SMN1 deletions, while sequencing can help identify certain variants within the gene.
For this reason, the appropriate testing method should be selected according to the clinical situation and laboratory methodology.
What Is NGS Genetic Testing?
Next-Generation Sequencing (NGS) is a technology that can analyze DNA sequences rapidly and in detail.
NGS may be used to investigate genetic changes in individual genes or groups of genes. In suspected SMA, the testing approach should be appropriate for detecting the types of SMN1 alterations associated with the condition.
A genetic report should always be interpreted together with the individual’s symptoms, medical history, and other relevant clinical information.
When Should Someone Consider SMA Genetic Testing?
Genetic testing may be considered when a healthcare professional suspects SMA based on symptoms, neurological findings, or family history.
Testing may be particularly relevant for individuals with unexplained progressive muscle weakness, delayed motor development, loss of previously acquired motor abilities, or a known family history of SMA.
Genetic counselling can also help families understand inheritance, test results, and potential implications for relatives.
Why Is Early Diagnosis Important?
Early recognition of SMA can help families and healthcare professionals understand the cause of unexplained muscle weakness and make appropriate clinical decisions.
Because SMA can progress differently from one person to another, identifying the underlying genetic cause can provide valuable information for clinical management and family counselling.
SMN1 Genetic Testing for SMA in Nigeria
Spinal Muscular Atrophy can affect people at different stages of life, from infancy through adulthood. Recognizing the symptoms and understanding the role of the SMN1 gene can help support timely evaluation.
For individuals being evaluated for SMN1-related SMA, including SMA Type 3, genetic testing may provide important molecular information.
DNA Labs Nigeria offers an SMN1 Gene Spinal Muscular Atrophy Type 3 NGS Genetic DNA Test for individuals undergoing genetic evaluation for this condition.
Conclusion
Spinal Muscular Atrophy is a genetic neuromuscular disorder that can affect children and adults. Symptoms can range from severe weakness during infancy to gradually progressive weakness in adulthood.
Because SMA is strongly associated with changes in the SMN1 gene, genetic testing plays an important role in establishing a molecular diagnosis.
If SMA is suspected, speak with a qualified healthcare professional about appropriate clinical evaluation and whether SMN1 genetic testing may be suitable.
FAQs:
Can adults have Spinal Muscular Atrophy?
Yes. Although some forms of SMA begin during infancy or childhood, later-onset and adult-onset forms can also occur.
Is SMA a genetic condition?
Yes. The most common 5q form of SMA is associated with pathogenic variants affecting both copies of the SMN1 gene and is inherited in an autosomal recessive pattern.
What gene is associated with SMA?
The SMN1 gene is the primary gene associated with the most common form of spinal muscular atrophy.
Does SMN2 determine SMA severity?
SMN2 copy number can influence the clinical presentation, but it does not perfectly predict disease severity or progression.
Can genetic testing confirm SMA?
Appropriate molecular genetic findings in SMN1 can establish a diagnosis of 5q SMA when interpreted in the appropriate clinical context.
